Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Active
HT9402-26-Q-9401Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Department of War, through the Defense Health Agency, is soliciting quotations to support the establishment and maintenance of the Uniform Formulary for the Military Health System, as mandated by federal law and regulation. The process involves evaluating pharmaceutical agents for clinical and cost effectiveness to determine their placement on the formulary tiers—generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary—with the goal of optimizing patient access and managing expenditures. The solicitation includes the potential award of Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program Agreements contingent upon the Pharmacy and Therapeutics Committee’s recommendations. Two drug classes are under review for the November 2026 meeting: Atopy—Topical Agents including Anzupgo, Eucrisa, Opzelura, Vtama, and Zoryve; and Lung Cancer—METEX14, including Tabrecta and Tepmetko. The request for quotation, identified as HT9402-26-Q-9401, outlines detailed procedures, appendices for BPA and ADP, and key submission deadlines. Responses are required by October 1, 2026, with a mandatory pre-quotation teleconference scheduled for August 12, 2026. The solicitation is issued by the Defense Health Agency under the Department of Defense, with the primary point of contact located in Aurora, Colorado, and performance expected in Texas. Vendors must adhere strictly to the instructions provided in the RFQ to ensure eligibility for consideration under the uniform formulary program, which directly impacts pharmacy benefits for military personnel and their dependents.

General Info

Defense Health Agency seeks quotes to evaluate and include drugs in Military Health System formulary by October 1, 2026.

Agency

Department Of Defense → Defense Health AgencyView Agency

NAICS

325412 - Pharmaceutical Preparation ManufacturingView NAICS

Place of Performance

TX, 78230, USA

Set-Aside

NONE

Documents

(5)

RFQ HT9402-26-Q-9401 Department of War Uniform Formulary

PDFrfq

November 2026 P&T Meeting Reporting - Pharmacy Operations Support Contract

XLSXreport

UF BPA NDC Price List for Lung Cancer METEX14 November 2026

XLSXbpa-price-list

UF BPA NDC Price List for Atopy Topical Agents November 2026

XLSXbpa-price-list

NDC Price List FAQ for RFQ Submission

PDFfaq

AI Contract Breakdown

Uniform Contract Format

What is UCF?

Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseSolicitation
Posted

Solicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Defense Health Agency
Contacts2 people available
OfficeAURORA, CO, 80011, USA
Organization / Agency
Department Of Defense → Defense Health Agency
View Agency Profile
Office AddressAURORA, CO, 80011, USA
Contacts
Stephanie Erpelding

Full Description

Show more

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.



P&T COMMITTEE MEETING: The following November 2026 drug classes/subclasses will be reviewed:


a. Atopy - Topical Agents


  • Anzupgo 
  • Eucrisa 
  • Opzelura
  • Vtama
  • Zoryve

b. Lung Cancer - METEX14


  • Tabrecta
  • Tepmetko

The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9401. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference.

Similar Contracts

Same NAICS industry code

NAICS: 325412
New
Federal
Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Solicitation # HT9402-26-Q-9402
The Department of War, through the Defense Health Agency, is soliciting quotes under RFQ HT9402-26-Q-9402 to support the establishment and maintenance of the Uniform Formulary for the Military Health System, as mandated by 10 U.S.C. § 1074g and 32 CFR § 199.21. The process involves evaluating pharmaceutical agents for clinical and cost effectiveness to determine placement on the Uniform Formulary as generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary, with the goal of optimizing pharmaceutical procurement through Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program Agreements. Four newly approved drugs—Awiqli Flextouch (basal insulin), Cavhanza (BCR-ABL tyrosine kinase inhibitor for leukemia and lymphoma), Lipfendra (PCSK9 antilipidemic), and Trutakna (nephrology agent)—are scheduled for review at the November 2026 Pharmacy and Therapeutics Committee meeting, and industry responses will inform their inclusion or exclusion. Responses to the RFQ are due by August 27, 2026, with a pre-quotation teleconference scheduled for August 12, 2026, to clarify requirements. Clinical data submissions for evaluation must be sent via email to the designated point of contact by the deadline specified in Part 2.3.2. The solicitation, issued by the Defense Health Agency under NAICS code 325412, is managed from Aurora, Colorado, with performance centered in San Antonio, Texas. Primary contact is Julia Trang, with Stephanie Erpelding as secondary contact, and all submissions and inquiries must adhere to the instructions outlined in RFQ HT9402-26-Q-9402 to be considered valid.
Defense Health Agency

POSTED

about 7 hours ago

DEADLINE

in 21 days
View Details
NAICS: 325412
New
DIBBS
Veterinary Pharmaceutical Tablet SupplierThe contract requires the manufacture and supply of Maropitant Citrate 160mg veterinary tablets packaged in blister packs containing four tablets per sheet, fully compliant with FDA and Defense Logistics Agency specifications. The product must meet all regulatory and quality standards for veterinary use, with strict adherence to packaging, labeling, and stability requirements to ensure efficacy and safety during storage and transport. The supplier is expected to deliver consistent, high-quality output in accordance with pharmaceutical manufacturing best practices, and all materials must be traceable and documented to support federal procurement compliance. This subcontract is issued under the Medical Supply Chain Pharm FSA, a division of the Department of Defense, with performance required at the APO ZIP code 09227-0000. The solicitation was posted on August 5, 2026, and responses are due by August 11, 2026, indicating a tight turnaround for proposals. The NAICS code 325412 identifies this as a pharmaceutical and biological product manufacturing contract, emphasizing the technical and regulatory expertise necessary for participation. While no set-aside details are provided, the contract is open to qualified subcontractors capable of meeting DoD’s stringent pharmaceutical supply chain requirements, with all deliverables aligned to ensure uninterrupted availability of critical veterinary medications for military and associated personnel.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
OATMEAL, COLLOIDAL CONC
Solicitation # SPE2DP-26-T-4504
The contract is for Oatmeal, Colloidal Concentrate, a medical supply regulated by the FDA, sourced under the Johnson & Johnson/NDC 81370-0364-00 specification. Each unit is packaged as 8 packets per PG unit, with a total requirement of 3 PG, equating to 24 individual packets. The item carries a non-extendable shelf life of 36 months and must comply with Medical Marking Standard No. 1, replacing all references to MIL-STD-129. Packaging must adhere to MIL-STD-2073-1E, ensuring sealed unit containers protect contents from damage during transport and are packed in commercially suitable exterior containers for safe, cost-effective delivery to the destination point. All markings and labeling must meet DLA medical standards, and copies of the marking guide are available via DLA Troop Support. The contract is issued under solicitation SPE2DP-26-T-4504 with a response deadline of August 11, 2026, and a delivery requirement of 20 days after award, FOB destination. The NSN is 6505-01-442-2051, and quantity variance is strictly zero percent with no tolerance for over or under delivery. Inspection and acceptance occur at the delivery point. The purchase request number is 7017749529, and pricing is set at a unit price of $3.00 per PG. The contracting official must submit a referral in EBS to confirm product compliance, including manufacturer and bidder details. The item falls under NAICS code 325412 and is managed by the Department of Defense’s Medical Supply Chain PHARM FSA office. The delivery location is Fort Campbell, and all requirements are subject to DLA’s master list of technical and quality specifications as referenced by RP001 and RA001.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
WATER FOR IRRIGATIO
Solicitation # SPE2DP-26-T-4512
Water for Irrigation, Sterile, USP, is a 1000 mL sterile, distilled, and nonpyrogenic solution supplied in semi-rigid plastic containers with screw caps, intended exclusively for irrigation, washing, rinsing, and dilution purposes and not for injection by usual parenteral routes. Each package contains twelve units and is identified by NSN 6505-01-075-0679 and NDC 00338-0004-04, manufactured by Baxter Healthcare Corporation. The product must be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F), protected from freezing and excessive heat, with a non-extendable shelf life of 36 months. Packaging and labeling must strictly adhere to the latest Medical Marking Standard No. 1 and MIL-STD-129, with commercial packaging in compliance with ASTM D3951 unless otherwise specified by DLA’s Master List of Technical and Quality Requirements, which take precedence. All shipments are to be delivered FOB destination within five days, with zero variance allowed in quantity, and are subject to inspection and acceptance at the delivery point. The item is regulated by the FDA, and contractor submissions require referral through EBS for confirmation. Delivery is directed to multiple U.S. Navy vessels across FPO addresses, with specific shipment instructions prohibiting parcel post and requiring traceable transport methods. Palletization and packaging follow DLA’s RP001 requirements, and each order line item is tied to unique contract line item numbers, purchase requests, and delivery schedules ranging from March through August 2026.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
MOXIFLOXACIN HYDROCHLO
Solicitation # SPE2DP-26-T-4509
Moxifloxacin Hydrochloride Tablets, 400 mg in 30-tablet bottles, are being procured under solicitation SPE2DP-26-T-4509 with a total quantity of 8 bottles, each containing 30 tablets, for delivery within 20 days FOB destination. The item is regulated by the FDA and must comply with the Medical Marking Standard No. 1 dated February 4, 2013, which supersedes all references to MIL-STD-129. Packaging must meet commercial standards as specified in the procurement document, with each unit sealed in a container that protects against damage or breakage and packed in suitable exterior shipping containers to ensure safe delivery at the lowest carrier rate. The product has a non-extendable shelf life of 36 months and must be stored at controlled room temperature, avoiding high humidity. Accepted manufacturers include TEVA PHARMACEUTICALS USA, INC. and RISING PHARMA HOLDINGS, INC., with designated NDC numbers. The contract requires strict adherence to DLA’s Master List of Technical and Quality Requirements, and any covered defense information must be marked in accordance with the latest edition of Medical Marking Standard No. 1. Inspection and acceptance occur at the destination with zero variance permitted in quantity. A referral must be sent via EBS to the product specialist confirming bidder, manufacturer, and product details prior to award.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
WATER FOR INJECTION, ST
Solicitation # SPE2DP-26-T-4510
Water for Injection, Sterile, USP, is procured in 20ml vials with flip-top closures, packaged in units of 25 vials per package, with a non-extendable shelf life of 24 months. The product must be stored at controlled room temperature between 20–25°C (68–77°F) and marked in accordance with the latest edition of the Medical Marking Standard No. 1. Technical and quality requirements are governed by the DLA Master List of Technical and Quality Requirements, with compliance determined by the revision in effect on the solicitation or award date, depending on acquisition size. The item is regulated by the FDA and requires a referral through EBS to confirm bidder and manufacturer details, including NDC numbers for Hospira Worldwide LLC (NDC 00409-4887-20) and Fresenius Kabi, LLC (NDC 63323-0185-20). The NSN is 6505005825079, with a single package quantity of one unit. Delivery is required within 20 days to Fort Campbell, Kentucky, FOB destination, with no variance allowed in quantity. Inspection and acceptance occur at the delivery point. Packaging must comply with MIL-STD-2073-1E, and government identification must be removed from non-accepted supplies. The solicitation is issued under SPE2DP-26-T-4510, with a response deadline of August 11, 2026, and is classified under NAICS code 325412 by the Department of Defense’s Medical Supply Chain PHARM FSA.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
LEVONORGESTREL AND ETH
Solicitation # SPE2DP-26-T-4515
The contract specifies the procurement of LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS, USP, a hormonal contraceptive product regulated by the FDA, supplied by TEVA PHARMACEUTICALS USA, INC. Each package contains 168 tablets organized into six cycles of 28 tablets each, with a controlled sequence of active and inert tablets: six tablets with 50 mcg levonorgestrel and 30 mcg ethinyl estradiol, followed by five tablets with 75 mcg levonorgestrel and 40 mcg ethinyl estradiol, ten tablets with 125 mcg levonorgestrel and 30 mcg ethinyl estradiol, and seven inert tablets. The unit of issue is one package (PG) equaling 168 tablets, with a total order of two packages. The product must have a minimum of 21 months of remaining shelf life at the time of receipt by the first government activity, with a full 24-month shelf life from manufacture. Storage must be maintained at controlled room temperature between 20°C and 25°C (68°F to 77°F). Packaging and labeling must comply strictly with Medical Marking Standard No. 1A dated February 4, 2013, replacing all references to MIL-STD-129, and all units must be sealed in commercial containers that protect against damage and ensure safe, cost-effective delivery to Fort Campbell, TN, with delivery required within 20 days. The product is subject to federal acquisition regulations and requires pre-award confirmation through the EBS referral system, including manufacturer and product identification. The NSN is 6505012240176, the solicitation number is SPE2DP-26-T-4515, and the contract is awarded under a no-variance quantity agreement with FOB destination terms.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
ENROFLOXACIN INJECT
Solicitation # SPE2DP-26-T-4496
Enrofloxacin Injection, a veterinary antibiotic solution for dogs, is supplied at a concentration of 2.27% with a dosage of 2.5 mg per kilogram in a 20 mL volume, intended for intramuscular use in managing bacterial pathogens. The product is regulated by the FDA and requires strict adherence to shelf-life requirements, with a non-extendable shelf life of 24 months classified as a Type I (Code M) item. Storage must be maintained at or below 25 degrees Celsius with excursions permitted up to 40 degrees Celsius, and the product must be protected from direct sunlight and freezing. Packaging and marking must conform to the latest edition of the Medical Marking Standard No. 1, superseding all references to MIL-STD-129, and all units must be sealed in commercial containers designed to prevent damage and ensure safe transport. The item is procured under contract SPE2DP-26-T-4496 with a single unit of issue, delivered FOB destination within 81 days, with zero variance tolerance. Delivery is directed to the U.S. Medical Material Center in Kaiserslautern, Germany, with the required delivery date set for August 5, 2026. Supplier information includes Patterson Veterinary Supply, Inc. and Covetrus North America, LLC with designated part numbers, and all technical and quality requirements are governed by the DLA Master List of Technical and Quality Requirements. The contracting official must submit a referral via EBS for FDA-regulated product confirmation prior to award, including manufacturer and bidder details.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
NEOMYCIN AND POLYMYXIN
Solicitation # SPE2DP-26-T-4500
The contract covers the procurement of Neomycin and Polymyxin B Sulfates and Gramicidin, a regulated pharmaceutical product with NDC number 24208-0790-62, supplied by Bausch & Lomb Pharmaceuticals Division under the Veteran’s Health Joint Venture program. The item is classified as a TYPE I (CODE Q) with a strict non-extendable shelf life of 36 months, and all packaging must comply with Medical Marking Standard No. 1, superseding MIL-STD-129. Each unit must be sealed in a protective container and shipped in commercial exterior packaging suitable for safe transport by common carrier at the lowest cost to the delivery point, with all markings adhering to DLA’s medical marking standards. The product is subject to FDA regulation, requiring contracting officials to verify its status via EBS referral prior to award. The delivery is FOB destination, with required shipment within five days of award, and no quantity variance is permitted. The contract includes the NSN 6505-01-143-4643 and references the DLA Master List of Technical and Quality Requirements for applicable specifications, with the solicitation number SPE2DP-26-T-4500 and response deadline set for August 11, 2026. The item is procured under the authorized unit of issue BT (10 mL), with a total quantity of 3 units, and performance is to occur at Fort Lewis, WA. The contract is governed under federal acquisition protocols, and supplier submissions must include detailed information on the bidder, manufacturer, part number, and product description. All packaging and labeling must meet DLA’s technical and quality standards as defined in their official documentation.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details

More opportunities from Department Of Defense → Defense Health Agency

Same awarding agency

NAICS: 621340
New
Federal
Audio Hazard Screening Services
Solicitation # HT001426QE022
This solicitation, identified as HT001426QE022, is issued by the Defense Health Agency under the Department of Defense and results in a Blanket Purchase Agreement with a five-year ordering period from August 15, 2026, to August 14, 2031. The contract is a Small Business Set Aside under NAICS code 621340 and follows a Lowest Price Technically Acceptable source selection process, where technical acceptability is determined first, and award is made to the offeror with the lowest evaluated price among those meeting all requirements. The contractor will provide comprehensive audiologic services including audiometric testing, tympanometry, acoustic reflex testing, otoacoustic emissions, auditory brainstem response, central auditory processing, videonystagmography, and vestibular evoked myogenic potential testing at a location within a 60-mile radius of Rock Island Arsenal, Illinois, with final delivery and acceptance occurring at Fort Campbell, Kentucky. Services must conform to standards set by the Joint Commission and the American Medical Association, and all personnel must be licensed audiologists. The contractor is prohibited from billing patients or third parties and must comply with HIPAA regulations, safeguarding Protected Health Information, and maintaining strict confidentiality of medical records without government approval. All records must be retained for at least three years after final payment and are subject to audit by the Comptroller General. Proposals must be submitted electronically via email to the specified contracting officials by 1:00 PM EST on August 12, 2026, the revised closing date following Amendment #2, and must include a signed statement of compliance, a detailed technical description of services aligned with the Performance Work Statement, and complete pricing using the provided Blanket Purchase Agreement format. Offerors must be registered in SAM.gov and hold a valid Unique Entity ID and CAGE code, and are required to represent their small business status and any applicable socioeconomic certifications. The contract includes mandatory clauses addressing security, safeguarding of defense information, compliance with prohibitions regarding telecommunications equipment from restricted regions, and representation of no involvement with the Maduro regime or the Xinjiang Uyghur Autonomous Region. Invoicing must be conducted exclusively through Wide Area WorkFlow using specified submission types such as Invoice 2in1 for service delivery, and payment inquiries and acceptance are handled by Jason Honeycutt at Fort Campbell. The contractor must designate a point of contact to the Contracting Officer and Contracting Officer’s Representative within
Offices of Physical, Occupational and Speech Therapists, and Audiologists

POSTED

1 day ago

DEADLINE

in 6 days
View Details
NAICS: 541513
New
Federal
Program Executive Office Defense Healthcare Management Systems’ (PEO DHMS) Enterprise Software Services (ESS) Next
Solicitation # HT003826SC003
The Defense Health Agency Contracting Activity is issuing a Commercial Solutions Opening for Enterprise Support Services Next under solicitation number HT003826SC003, aimed at securing advanced software services to support the Program Executive Office for Defense Healthcare Management Systems. This solicitation remains open until August 20, 2026, at 3:00 PM CST, with the possibility of updates prior to closure. Respondents may submit proprietary or sensitive information, but must clearly mark such material to ensure it is safeguarded from unauthorized disclosure, limited to government personnel unless explicit permission is granted for support contractors to access it. Two designated organizations, Boston Consulting Group and Andrew Morgan, LLC, are contractually bound by organizational conflict of interest and confidentiality clauses to protect submitted proprietary data. Submission to this CSO automatically grants the government authority to involve non-government advisors in evaluating proposals; companies with concerns about third-party access to sensitive information are urged to contact the listed point of contacts before submitting. The contract is administered by the Department of Defense through the Defense Health Agency, with the primary office located in Rosslyn, Virginia, and no set-aside provisions apply. Primary and secondary points of contact are Krystal Mason and J R Oliver, respectively, for inquiries regarding the solicitation.
Computer Facilities Management Services

POSTED

1 day ago

DEADLINE

in 14 days
View Details
NAICS: 541511
New
Federal
Request for Solutions (RFS): Autonomous Coding (AC) and Automated Appeals & Denials Management (ADM)
Solicitation # HT0038RFSACADM
The Defense Healthcare Management Systems Modernization Program Management Office, under the Department of Defense’s Defense Health Agency, is soliciting innovative AI and machine learning solutions to transform healthcare billing and financial recovery operations within the Military Health System. This Request for Solutions, issued under 10 U.S.C. § 4022, aims to award one or more prototype Other Transaction Agreements to industry partners capable of delivering advanced, autonomous systems that operate without human intervention while remaining fully auditably and explainable. Two distinct capability areas are targeted: Autonomous Coding, which must accurately assign medical billing codes from clinical documentation using human-like AI processes, and Automated Appeals & Denials Management, which must systematically reduce aged accounts receivable, increase first-pass claim success, expedite documentation release, and automate the generation and submission of appeals to third-party payers. Industry participants may respond to one or both capability areas. Solicitation HT0038RFSACADM, posted on August 5, 2026, requires responses by August 19, 2026, and is governed by NAICS code 541511 for custom computer programming services. Proposals must be submitted to the Defense Health Agency’s office located in Rosslyn, Virginia, with all technical and procedural instructions detailed in the attached documentation. Primary point of contact is Sharjeel Javaid, with Dominique Brown serving as secondary contact, both reachable via official government email addresses. The opportunity is open to all qualified entities without set-aside restrictions, and performance will be conducted across Virginia. Interested parties are directed to the SAM.gov portal for full solicitation materials and submission guidelines, with emphasis placed on adherence to all requirements to ensure eligibility for consideration.
Custom Computer Programming Services

POSTED

1 day ago

DEADLINE

in 13 days
View Details